Grand Pharmaceutical Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Public

  • Employees
  • 12,326

Employees

  • Stock Symbol
  • 00512

Stock Symbol

  • Investments
  • 45

  • Share Price
  • $0.55
  • (As of Friday Closing)

Grand Pharmaceutical General Information

Description

Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology products, manufacture and sales of bio-technology products as well as manufacture and sales of nuclear medicine anti-tumor diagnosis and treatment and cerebro-cardiovascular precision interventional diagnosis and treatment technology products, in the People's Republic of China. The operation of the group constitutes one single reportable segment. The company has presence in The PRC, America, Europe, Asia other than the PRC and Others. The majority of revenue comes from the PRC. Its brands are breathe, biology, Cardiovascular emergency care, Cardiovascular intervention, ENT, tumor.

Contact Information

Formerly Known As
China Grand Pharmaceutical and Healthcare Holdings Ltd, Maxx Bioscience Holdings, China Grand Pharmaceutical Healthcare Holdings Limited, China Apollo Holdings Limited, MAXX Bioscience Holdings Limited
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 23rd Floor, City Plaza
  • Number 160 Qiaokou Road, Qiaokou District
  • Wuhan, Hubei 430034
  • China
+86 027
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
HKG
Corporate Office
  • 23rd Floor, City Plaza
  • Number 160 Qiaokou Road, Qiaokou District
  • Wuhan, Hubei 430034
  • China
+86 027

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Grand Pharmaceutical Stock Performance

As of 13-Nov-2026, Grand Pharmaceutical’s stock price is $0.55. Its current market cap is $1.93B with 3.5B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.55 $0.55 $0.53 - $1.14 $1.93B 3.5B 4.37M $0.04

Grand Pharmaceutical Financials Summary

As of 30-Jun-2026, Grand Pharmaceutical has a trailing 12-month revenue of $1.6B.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 2,458,521 3,923,882 2,456,096 2,135,483
Revenue 1,597,890 1,575,526 1,492,311 1,344,911
EBITDA 194,290 286,154 452,381 374,726
Net Income 141,989 159,162 316,326 240,126
Total Assets 3,585,070 3,491,226 3,219,059 2,881,298
Total Debt 644,200 606,880 572,235 435,642
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Grand Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Grand Pharmaceutical‘s full profile, request access.

Request a free trial

Grand Pharmaceutical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Grand Pharmaceutical Group Ltd are principally engaged in the manufacture and sales of pharmaceutical technology product
Drug Discovery
Wuhan, China
12,326 As of 2026

Basel, Switzerland
 

Ahmedabad, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Grand Pharmaceutical Competitors (21)

One of Grand Pharmaceutical’s 21 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
Torrent Pharmaceuticals Corporation Ahmedabad, India
Cipla Corporation Mumbai, India
Aurobindo Pharma Corporation Hyderabad, India
Sun Pharmaceutical Industries Corporation Mumbai, India
You’re viewing 5 of 21 competitors. Get the full list »

Grand Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Grand Pharmaceutical Investments & Acquisitions (45)

Grand Pharmaceutical’s most recent deal was a Later Stage VC with Cavendish (Drug Discovery). The deal was made on 22-Oct-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cavendish (Drug Discovery) 22-Oct-2026 Later Stage VC Drug Discovery
Tianjin Tanabe 22-Jul-2024 Merger/Acquisition Pharmaceuticals
Xeltis 30-Jun-2023 Later Stage VC Therapeutic Devices
BlackSwan Vascular 24-Apr-2023 Merger/Acquisition Medical Supplies
Hubei Bafeng Pharmaceutical 07-Aug-2022 Merger/Acquisition Other Pharmaceuticals and Biotechnology
You’re viewing 5 of 45 investments and acquisitions. Get the full list »

Grand Pharmaceutical ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

28.45 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Grand Pharmaceutical’s complete esg history, request access »

Grand Pharmaceutical Exits (5)

Grand Pharmaceutical’s most recent exit was on 01-Jan-2022 from Cloudbreak Pharma. The exit was categorized as with 11 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Cloudbreak Pharma 01-Jan-2022 Completed
  • 11 buyers
Cloudbreak Pharma 16-Apr-2020 Completed
  • 4 buyers
Oncosec Medical 10-Feb-2020 Completed
  • 2 buyers
Conavi Medical 15-Nov-2017 Completed
Henan Lihua Pharmaceutical 30-Apr-2010 Merger/Acquisition Completed
To view Grand Pharmaceutical’s complete exits history, request access »

Grand Pharmaceutical Affiliates

Subsidiaries (9)

Name Industry Location Year Founded
Shenzhen Sun God Sales Shenzhen, China 2004
Puer Weiye Beijing, China 2004
Hubei Bafeng Pharmaceutical Enshi, China 1997
Zhejiang Xianle Taizhou, China 1995
Tianjin Tanabe Tianjin, China 1993
You’re viewing 5 of 9 affiliates. Get the full list.  »

Grand Pharmaceutical FAQs

  • When was Grand Pharmaceutical founded?

    Grand Pharmaceutical was founded in 1995.

  • Where is Grand Pharmaceutical headquartered?

    Grand Pharmaceutical is headquartered in Wuhan, China.

  • What is the size of Grand Pharmaceutical?

    Grand Pharmaceutical has 12,326 total employees.

  • What industry is Grand Pharmaceutical in?

    Grand Pharmaceutical’s primary industry is Drug Discovery.

  • Is Grand Pharmaceutical a private or public company?

    Grand Pharmaceutical is a Public company.

  • What is Grand Pharmaceutical’s stock symbol?

    The ticker symbol for Grand Pharmaceutical is 00512.

  • What is the current stock price of Grand Pharmaceutical?

    As of 13-Nov-2026 the stock price of Grand Pharmaceutical is $0.55.

  • What is the current market cap of Grand Pharmaceutical?

    The current market capitalization of Grand Pharmaceutical is $1.93B.

  • What is Grand Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Grand Pharmaceutical is $1.6B.

  • Who are Grand Pharmaceutical’s competitors?

    Novartis, Torrent Pharmaceuticals, Cipla, Aurobindo Pharma, and Sun Pharmaceutical Industries are some of the 21 competitors of Grand Pharmaceutical.

  • What is Grand Pharmaceutical’s annual earnings per share (EPS)?

    Grand Pharmaceutical’s EPS for 12 months was $0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process